Skip to main content
Erschienen in: Annals of Surgical Oncology 3/2008

01.03.2008 | Bone and Soft Tissue Sarcomas

Tumor Necrosis Rate Adjusted by Tumor Volume Change Is a Better Predictor of Survival of Localized Osteosarcoma Patients

verfasst von: Min Suk Kim, MD, Soo-Yong Lee, MD, Wan Hyeong Cho, MD, Won Seok Song, MD, Jae-Soo Koh, MD, Jun Ah Lee, MD, Ji Young Yoo, MD, Dae-Geun Jeon, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

We assessed whether new parameter that considers both tumor volume change and necrosis rate predicts metastasis-free survival of localized osteosarcoma patients. We also evaluated relationship between tumor volume change and necrosis rate or metastasis-free survival.

Methods

We retrospectively reviewed 151 patients with stage II osteosarcoma who were treated with surgery and neoadjuvant chemotherapy. The tumor volume change was measured and calculated based on pre- and postchemotherapy magnetic resonance images. The mean metastasis-free interval was 83.1 months. We calculated adjusted tumor necrosis rate as following formula: 100–(100–necrosis rate) × postchemotherapy/prechemotherapy tumor volume. Survival and logistic regression analyses were used to evaluate the correlation among size parameters, tumor necrosis rate and survival.

Results

The 5-year metastasis-free survival rate of 151 patients was 71.4% (95% CI, 67.7–75.1%). American Joint Committee on Cancer (AJCC) stage IIB (RR 2.27; 95% CI, 1.11–4.62; P = 0.025) and poor adjusted tumor necrosis rate (RR 2.02; 95% CI, 1.05–3.89; P = 0.035) independently correlated with metastasis-free survival period. Further, tumor volume change independently correlated with necrosis rate. Decreased tumor volume could predict good response, with sensitivity of 80.2%, specificity of 68.6%, and positive predictive value (PPV) of 74.7%. Increased or stable tumor volume could predict poor response, with sensitivity of 68.6%, specificity of 80.2%, and PPV of 75.0 %.

Conclusion

The necrosis rate adjusted by the tumor volume change is an independent prognostic factor in osteosarcoma. This adjusted tumor necrosis rate may serve as a basis for risk-adapted therapy in combination with other prognostic factors.
Literatur
1.
Zurück zum Zitat Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20:776–90PubMedCrossRef Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20:776–90PubMedCrossRef
2.
Zurück zum Zitat Mankin HJ, Hornicek FJ, Rosenberg AE, et al. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res 2004; 429:286–91PubMedCrossRef Mankin HJ, Hornicek FJ, Rosenberg AE, et al. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res 2004; 429:286–91PubMedCrossRef
3.
Zurück zum Zitat Bacci G, Mercuri M, Longhi A, et al. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer 2005; 41:2079–85PubMedCrossRef Bacci G, Mercuri M, Longhi A, et al. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer 2005; 41:2079–85PubMedCrossRef
4.
Zurück zum Zitat Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: A critical review. J Clin Oncol 1994; 12:423–31PubMed Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: A critical review. J Clin Oncol 1994; 12:423–31PubMed
5.
Zurück zum Zitat Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: Results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988; 6:329–37PubMed Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: Results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988; 6:329–37PubMed
6.
Zurück zum Zitat Holscher HC, Hermans J, Nooy MA, et al. Can conventional radiographs be used to monitor the effect of neoadjuvant chemotherapy in patients with osteogenic sarcoma? Skeletal Radiol 1996; 25:19–24PubMedCrossRef Holscher HC, Hermans J, Nooy MA, et al. Can conventional radiographs be used to monitor the effect of neoadjuvant chemotherapy in patients with osteogenic sarcoma? Skeletal Radiol 1996; 25:19–24PubMedCrossRef
7.
Zurück zum Zitat Wellings RM, Davies AM, Pynsent PB, et al. The value of computed tomographic measurements in osteosarcoma as a predictor of response to adjuvant chemotherapy. Clin Radiol 1994; 49:19–23PubMedCrossRef Wellings RM, Davies AM, Pynsent PB, et al. The value of computed tomographic measurements in osteosarcoma as a predictor of response to adjuvant chemotherapy. Clin Radiol 1994; 49:19–23PubMedCrossRef
8.
Zurück zum Zitat Holscher HC, Bloem JL, van der Woude HJ, et al. Can MRI predict the histopathological response in patients with osteosarcoma after the first cycle of chemotherapy? Clin Radiol 1995; 50:384–90PubMedCrossRef Holscher HC, Bloem JL, van der Woude HJ, et al. Can MRI predict the histopathological response in patients with osteosarcoma after the first cycle of chemotherapy? Clin Radiol 1995; 50:384–90PubMedCrossRef
9.
Zurück zum Zitat Dyke JP, Panicek DM, Healey JH, et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology 2003; 228:271–8PubMedCrossRef Dyke JP, Panicek DM, Healey JH, et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology 2003; 228:271–8PubMedCrossRef
10.
Zurück zum Zitat Soderlund V, Larsson SA, Bauer HC, et al. Use of 99mTc-MIBI scintigraphy in the evaluation of the response of osteosarcoma to chemotherapy. Eur J Nucl Med 1997; 24:511–5PubMedCrossRef Soderlund V, Larsson SA, Bauer HC, et al. Use of 99mTc-MIBI scintigraphy in the evaluation of the response of osteosarcoma to chemotherapy. Eur J Nucl Med 1997; 24:511–5PubMedCrossRef
11.
Zurück zum Zitat Schulte M, Brecht-Krauss D, Werner M, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 1999; 40:1637–43PubMed Schulte M, Brecht-Krauss D, Werner M, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 1999; 40:1637–43PubMed
12.
Zurück zum Zitat van der Woude HJ, Bloem JL, van Oostayen JA, et al. Treatment of high-grade bone sarcomas with neoadjuvant chemotherapy: The utility of sequential color doppler sonography in predicting histopathologic response. Am J Roentgenol 1995; 165:125–33 van der Woude HJ, Bloem JL, van Oostayen JA, et al. Treatment of high-grade bone sarcomas with neoadjuvant chemotherapy: The utility of sequential color doppler sonography in predicting histopathologic response. Am J Roentgenol 1995; 165:125–33
13.
Zurück zum Zitat Holscher HC, Bloem JL, Vanel D, et al. Osteosarcoma: Chemotherapy-induced changes at MR imaging. Radiology 1992; 182:839–44PubMed Holscher HC, Bloem JL, Vanel D, et al. Osteosarcoma: Chemotherapy-induced changes at MR imaging. Radiology 1992; 182:839–44PubMed
14.
Zurück zum Zitat Lawrence JA, Babyn PS, Chan HS, et al. Extremity osteosarcoma in childhood: Prognostic value of radiologic imaging. Radiology 1993; 189:43–7PubMed Lawrence JA, Babyn PS, Chan HS, et al. Extremity osteosarcoma in childhood: Prognostic value of radiologic imaging. Radiology 1993; 189:43–7PubMed
15.
Zurück zum Zitat Picci P, Bacci G, Campanacci M, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. regional mapping of viable and nonviable tumor. Cancer 1985; 56:1515–21PubMedCrossRef Picci P, Bacci G, Campanacci M, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. regional mapping of viable and nonviable tumor. Cancer 1985; 56:1515–21PubMedCrossRef
16.
Zurück zum Zitat Rosen G, Marcove RC, Huvos AG, et al. Primary osteogenic sarcoma: Eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol 1983; 106 Suppl:55–67PubMedCrossRef Rosen G, Marcove RC, Huvos AG, et al. Primary osteogenic sarcoma: Eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol 1983; 106 Suppl:55–67PubMedCrossRef
17.
Zurück zum Zitat Salzer-Kuntschik M, Delling G, Beron G, et al. Morphological grades of regression in osteosarcoma after polychemotherapy - study COSS 80. J Cancer Res Clin Oncol 1983; 106 Suppl:21–4PubMedCrossRef Salzer-Kuntschik M, Delling G, Beron G, et al. Morphological grades of regression in osteosarcoma after polychemotherapy - study COSS 80. J Cancer Res Clin Oncol 1983; 106 Suppl:21–4PubMedCrossRef
18.
Zurück zum Zitat Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980; 153:106–20PubMed Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980; 153:106–20PubMed
19.
Zurück zum Zitat Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996; 14:848–58PubMed Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996; 14:848–58PubMed
20.
Zurück zum Zitat Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual, Sixth Edition. New York: Springer-Verlag, 2002 Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual, Sixth Edition. New York: Springer-Verlag, 2002
21.
Zurück zum Zitat Brisse H, Ollivier L, Edeline V, et al. Imaging of malignant tumours of the long bones in children: Monitoring response to neoadjuvant chemotherapy and preoperative assessment. Pediatr Radiol 2004; 34:595–605PubMedCrossRef Brisse H, Ollivier L, Edeline V, et al. Imaging of malignant tumours of the long bones in children: Monitoring response to neoadjuvant chemotherapy and preoperative assessment. Pediatr Radiol 2004; 34:595–605PubMedCrossRef
22.
Zurück zum Zitat van der Woude HJ, Bloem JL, Hogendoorn PC. Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing’s sarcoma: Review of current imaging modalities. Skeletal Radiol 1998; 27:57–71PubMedCrossRef van der Woude HJ, Bloem JL, Hogendoorn PC. Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing’s sarcoma: Review of current imaging modalities. Skeletal Radiol 1998; 27:57–71PubMedCrossRef
23.
Zurück zum Zitat Moon SH, Shin KH, Suh JS, et al. Tumor volume change after chemotheraphy as a predictive factor of disease free survival for osteosarcoma. Yonsei Med J 2005; 46:119–24PubMedCrossRef Moon SH, Shin KH, Suh JS, et al. Tumor volume change after chemotheraphy as a predictive factor of disease free survival for osteosarcoma. Yonsei Med J 2005; 46:119–24PubMedCrossRef
24.
Zurück zum Zitat Shin KH, Moon SH, Suh JS, et al. Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. Clin Orthop Relat Res 2000; 376:200–8PubMedCrossRef Shin KH, Moon SH, Suh JS, et al. Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. Clin Orthop Relat Res 2000; 376:200–8PubMedCrossRef
25.
Zurück zum Zitat Holscher HC, Bloem JL, Nooy MA, et al. The value of MR imaging in monitoring the effect of chemotherapy on bone sarcomas. Am J Roentgenol 1990; 154:763–9 Holscher HC, Bloem JL, Nooy MA, et al. The value of MR imaging in monitoring the effect of chemotherapy on bone sarcomas. Am J Roentgenol 1990; 154:763–9
26.
Zurück zum Zitat Glasser DB, Lane JM, Huvos AG, et al. Survival, prognosis, and therapeutic response in osteogenic sarcoma. the memorial hospital experience. Cancer 1992; 69:698–708PubMedCrossRef Glasser DB, Lane JM, Huvos AG, et al. Survival, prognosis, and therapeutic response in osteogenic sarcoma. the memorial hospital experience. Cancer 1992; 69:698–708PubMedCrossRef
27.
Zurück zum Zitat Ferrari S, Bertoni F, Mercuri M, et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: An analysis of 300 patients treated at the rizzoli institute. Ann Oncol 2001; 12:1145–50PubMedCrossRef Ferrari S, Bertoni F, Mercuri M, et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: An analysis of 300 patients treated at the rizzoli institute. Ann Oncol 2001; 12:1145–50PubMedCrossRef
28.
Zurück zum Zitat Edmonson JH, Green SJ, Ivins JC, et al. A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol 1984; 2:152–6PubMed Edmonson JH, Green SJ, Ivins JC, et al. A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol 1984; 2:152–6PubMed
29.
Zurück zum Zitat Taylor WF, Ivins JC, Unni KK, et al. Prognostic variables in osteosarcoma: A multi-institutional study. J Natl Cancer Inst 1989; 81:21–30PubMedCrossRef Taylor WF, Ivins JC, Unni KK, et al. Prognostic variables in osteosarcoma: A multi-institutional study. J Natl Cancer Inst 1989; 81:21–30PubMedCrossRef
30.
Zurück zum Zitat Spanier SS, Shuster JJ, Vander Griend RA. The effect of local extent of the tumor on prognosis in osteosarcoma. J Bone Joint Surg Am 1990; 72:643–53PubMed Spanier SS, Shuster JJ, Vander Griend RA. The effect of local extent of the tumor on prognosis in osteosarcoma. J Bone Joint Surg Am 1990; 72:643–53PubMed
31.
Zurück zum Zitat Petrilli AS, Gentil FC, Epelman S, et al. Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer 1991; 68:733–7PubMedCrossRef Petrilli AS, Gentil FC, Epelman S, et al. Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer 1991; 68:733–7PubMedCrossRef
32.
Zurück zum Zitat Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. european organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst 2000; 92:205–16PubMedCrossRef Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. european organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst 2000; 92:205–16PubMedCrossRef
33.
Zurück zum Zitat Onikul E, Fletcher BD, Parham DM, et al. Accuracy of MR imaging for estimating intraosseous extent of osteosarcoma. Am J Roentgenol 1996; 167:1211–5 Onikul E, Fletcher BD, Parham DM, et al. Accuracy of MR imaging for estimating intraosseous extent of osteosarcoma. Am J Roentgenol 1996; 167:1211–5
Metadaten
Titel
Tumor Necrosis Rate Adjusted by Tumor Volume Change Is a Better Predictor of Survival of Localized Osteosarcoma Patients
verfasst von
Min Suk Kim, MD
Soo-Yong Lee, MD
Wan Hyeong Cho, MD
Won Seok Song, MD
Jae-Soo Koh, MD
Jun Ah Lee, MD
Ji Young Yoo, MD
Dae-Geun Jeon, MD
Publikationsdatum
01.03.2008
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 3/2008
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9779-8

Weitere Artikel der Ausgabe 3/2008

Annals of Surgical Oncology 3/2008 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.